Halberd Corporation Selects University Research Partner
Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and signatures on the contract reflecting the agreed terms, is in process. Details will be released shortly. For more information please ...
Halberd Corporation CEO Answers Shareholders’ Questions Regarding Covid-19 Treatment
Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q: There are various extracorporeal medical procedures being researched or used and in various states of trial and approval. How do these differ from your patented process? A: All extracorporeal ...
Halberd Corporation Adds Dr. Abdon Nanhay to Scientific Advisory Board
Furthering the Fight Against Covid-19 Internationally Jackson Center, PA, August 10, 2020 – Halberd Corp. (OTC PINK: "HALB") today confirmed the addition of Dr. Abdon Nanhay as a member of the Scientific Advisory Board. Dr. Nanhay, a Brazilian physician, has over 25 years of experience in health and biological sciences. Dr. Nanhay’s experiences include general medicine practice, emergency medicine, health management, and coordination of clinical research. Dr. Nanhay also had worked for medical and educational ...
Halberd Corporation Secures $2 Million for Covid-19 Research
Jackson Center, PA, August 4, 2020 – Halberd Corp. (OTC PINK: "HALB") announced today that they have secured non-dilutive, grant-based funding for their patent pending Covid-19 treatment(s). Newly formed Nonprofit Organization, Epidemiologic Solutions Corporation, a Louisiana, Internal Revenue Code Section 501(c)(3) application pending, has committed to provide funding of approximately $2,000,000, as required by Halberd Corporation and its research partners William A. Hartman, Chairman, President & CEO of Halberd Corporation, stated, “Securing this funding will ...
Retired NFL Great Carl Eller Joins Halberd Corporation
Will Assist with Covid-19 Efforts and the Brain Jackson Center, PA, July 27, 2020 – Halberd Corp. (OTC PINK: "HALB") announced the appointment of Carl Eller, retired NFL Pro Football Hall of Famer, and President of the NFL Retired Players Association as a consultant. Mr. Eller’s expertise and contacts will be leveraged as part of Halberd Corporation’s work on brain injury caused by impact to the head (PTSD) and potential neurological changes associated with Covid-19. ...
Halberd Corporation CTO, Dr. Patricio Reyes, Presents Information at Virtual Event on Covid-19’s Effects on Neurological Functions
Jackson Center, PA, July 22, 2020 – Halberd Corporation (OTC Pink: HALB) announced their Chief Technical Officer and Head of Scientific Advisory Board, Dr. Patricio Reyes, presented A Community Information Session virtual event hosted yesterday by the Brain Injury Alliance of Arizona, on “Covid-19 & the Nervous System; Neurological Complications That Can Result”. Dr. Reyes has been requested to repeat this virtual event for the Arizona State Legislature at 2:30 PM (AZ Time) on Friday, ...